The accumulation of hypoxia-inducible factor-1α (HIF-1α) in the hypoxic tumor microenvironment has been confirmed to activate the downstream CD73–adenosine (CD73-ADO) pathway and lead to effector T cell exhaustion [108], which is a key disadvantage for the poor clinical efficacy of ICIs treatment [109]. The gene discussed is ADO; the disease is neoplasm.